Blood Test Predicts How Long Cancer Patients Will Survive
By LabMedica International staff writers Posted on 05 Jan 2017 |
Image: Midazolam, a drug used to give symptom relief in palliative care to terminal patients (Photo courtesy of WebMD).
Survival evaluations can determine whether or not pharmacological treatment should be given. Cytotoxic chemotherapy would rarely be prescribed in a patient unlikely to survive beyond several weeks because of unpleasant side effects.
The sedative midazolam is used for symptom relief in palliative care settings, but tolerance can develop if administered for two weeks or longer. Chronic midazolam treatment could therefore be recommended only for patients likely to die within a few weeks, and be contraindicated when predicted survival was longer than a month.
Scientists from Kyoto University (Japan) tested the predictive value of the models in cancer patients receiving palliative care. It was designed as a sub-analysis of the Japan prognostic assessment tools validation (J-ProVal) study, which compared the ability of four models to predict survival of advanced cancer patients in the real world. This sub-analysis included 1,015 patients, of whom 385 were based with palliative care teams in hospital, 464 were in palliative care units, and 166 were receiving palliative care services at home.
The current Six Adaptable Prognostic (SAP) models use three laboratory measurements, albumin, neutrophil, lactate dehydrogenase, which are routinely monitored in daily clinical practice with a blood test. The models can be used at any time point after the initiation of treatment, an important feature since a patient's condition can change. The team found that the SAP models showed a good performance for predicting the death occurrence within one to three months. The prediction was accurate in 75% to 80% of cases.
Yu Uneno, MD, an oncologist and lead author of the study, said, “Patients with advanced cancer and their families have to make decisions about treatment, where to spend the end-of-life, and when to discontinue palliative chemotherapy. Continuing ineffective therapy increases life-threatening adverse events, reduces quality of life, delays hospice referral, and deprives patients of the chance to die in their preferred place. Accurately predicting prognosis improves end-of-life care for cancer patients and their caregivers.” The study was presented on December 18, 2016, at the European Society for Medical Oncology Asia 2016 congress held in Singapore.
Related Links:
Kyoto University
The sedative midazolam is used for symptom relief in palliative care settings, but tolerance can develop if administered for two weeks or longer. Chronic midazolam treatment could therefore be recommended only for patients likely to die within a few weeks, and be contraindicated when predicted survival was longer than a month.
Scientists from Kyoto University (Japan) tested the predictive value of the models in cancer patients receiving palliative care. It was designed as a sub-analysis of the Japan prognostic assessment tools validation (J-ProVal) study, which compared the ability of four models to predict survival of advanced cancer patients in the real world. This sub-analysis included 1,015 patients, of whom 385 were based with palliative care teams in hospital, 464 were in palliative care units, and 166 were receiving palliative care services at home.
The current Six Adaptable Prognostic (SAP) models use three laboratory measurements, albumin, neutrophil, lactate dehydrogenase, which are routinely monitored in daily clinical practice with a blood test. The models can be used at any time point after the initiation of treatment, an important feature since a patient's condition can change. The team found that the SAP models showed a good performance for predicting the death occurrence within one to three months. The prediction was accurate in 75% to 80% of cases.
Yu Uneno, MD, an oncologist and lead author of the study, said, “Patients with advanced cancer and their families have to make decisions about treatment, where to spend the end-of-life, and when to discontinue palliative chemotherapy. Continuing ineffective therapy increases life-threatening adverse events, reduces quality of life, delays hospice referral, and deprives patients of the chance to die in their preferred place. Accurately predicting prognosis improves end-of-life care for cancer patients and their caregivers.” The study was presented on December 18, 2016, at the European Society for Medical Oncology Asia 2016 congress held in Singapore.
Related Links:
Kyoto University
Latest Pathology News
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities